Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 7481 Download: 111 Web of Science: 1 Crossref: 1

Original Article

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park, Soo Young Park

Clin Mol Hepatol. 2015;21(3):242-248. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.242

View: 8057 Download: 84 Web of Science: 5 Crossref: 3

7

The Korean Journal of Entecavir 1 mg therapy for Lamivudine-refractory chronic hepatitis B

Hyung Joon Kim

Clin Mol Hepatol. 2008;14(3):411-416. Published online September 30, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.3.411

View: 3891 Download: 15

3

Clinical and Virologic Characteristics of Lamivudine Resistance in HBV-associated Chronic Liver Disease

Sun Suk Kim, M.D., Moon Gi Chung, M.D., Ki Tak Ju, M.D., Dong Kyun Park, M.D. Oh Sang Kwon, M.D.,Yang Suh Koo, M.D., Yu Kyung Kim, M.D., Duck Ju Choi, M.D. Yu Jin Hwang, Ph.D.* and Ju Hyun Kim, M.D.

Clin Mol Hepatol. 2002;8(4):405-417. Published online January 1, 1970

View: 2218 Download: 15

1 |

Viewed By 5454	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5433	MAFLD: How is it different from NAFLD?
Viewed By 5318	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3982	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3977	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 78	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search